Drug
A166
A166 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_1
2
50%
Ph phase_3
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Completed2
Recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Trials by Status
recruiting125%
active_not_recruiting125%
completed250%
Recent Activity
2 active trials
Showing 4 of 4
completedphase_1
A Study of A166 in Patients With Advanced Solid Malignant Tumors
NCT05311397
recruitingphase_2
A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07299825
active_not_recruitingphase_3
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
NCT06968585
completedphase_1
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
NCT03602079
Clinical Trials (4)
Showing 4 of 4 trials
NCT05311397Phase 1
A Study of A166 in Patients With Advanced Solid Malignant Tumors
NCT07299825Phase 2
A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT06968585Phase 3
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
NCT03602079Phase 1
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4